Osteoclast inhibitors for knee conditions
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as knee pain.
Claims30
A method of treating osteoarthritis of the knee comprising administering zoledronic acid to a person in need thereof, wherein the zoledronic acid is administered at least twice, and the zoledronic acid is administered about every three months, or more frequently, wherein the zoledronic acid is administered in a dosage form that provides a bioavailabity of zoledronic acid of about 1.1% to about 3.2%.
A method of treating an osteoarthritis of the knee comprising:
- selecting a human patient having an osteoarthritis of the knee and OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing;
- and administering zoledronic acid to the human patient in need thereof, wherein the zoledronic acid is administered in a dosage form that provides a bioavailabity of zoledronic acid of about 1.1% to about 3.0%.
Dependencies are inferred from the claim text.